Leaman Life Sciences’ Post

Developments in inflammatory disease research are drawing in major investments. With advancements in immunology, the biopharma industry is buzzing with potential new therapies. Discover the notable deals of 2024 and why this market is so attractive to investors, here: https://lnkd.in/eiQ4awqK #Biopharma #Immunology #Inflammation #DrugDevelopment #Investment #HealthcareInnovation #MedicalResearch #NewTherapies

Sanofi aims to become the leading company in immunology. Our new R&D approach, which puts #immunoscience at the heart of our ambitions and future pipeline projects, drives this vision. As our Head of R&D and Executive Vice President, Houman Ashrafian explains in this insightful article, starting from the premise that many diseases have an immunological component, our R&D team is identifying the broader immune mechanisms that could help fight diseases across multiple therapeutic areas. This innovative approach to R&D has immense potential. By moving beyond traditional categorisations, we are opening new opportunities for therapeutic intervention, with the aim of helping more patients. It is a fundamental shift in healthcare. #AI, data science, and computational expertise are at the heart of this exciting landscape. They act as strategic tools to accelerate our research, providing new opportunities for progress and opening a new chapter in our research efforts. It is our acceleration process as the largest R&D-based pharmaceutical company in the European Union. It is also part of our transformation journey, which has led us to an industry-leading Phase 3 pipeline in immunology. We live in an incredible phase that can mark a new, astonishing step in pharmaceutical innovation. https://lnkd.in/dwMeS-RG #WeNeverSettle #Sanofi #Immunology

🔬 Exploring the Potential of IL-2 in Immunotherapy 🌟 In the realm of medical innovation, targeting regulatory T cells (Tregs) is opening up exciting possibilities. From checkpoint inhibitors to low-dose IL-2 and beyond, a myriad of strategies is emerging for therapeutic purposes. 🎯 Low-dose IL-2, in particular, takes center stage in this pursuit. It's not just about expanding Tregs; it's about supporting their survival and their suppressive superpowers. 💪 This makes IL-2 a pivotal tool in the arsenal against autoimmune diseases and transplantation challenges. 🩺 But, as with any promising therapy, there are hurdles to overcome. From precise dosing to addressing short half-lives and navigating the complex interplay between Tregs and effector T cells, the journey isn't without its challenges. ⚠️ Moreover, IL-2 therapy isn't one-size-fits-all. Patients' unique responses, potential immunosuppression, and the risk of resistance add layers of complexity. 💼💊 However, the story doesn't end there! Enter the world of engineered IL-2 variants, designed to boost stability and efficacy. From Aldesleukin to NKTR-214, ALT-803, and AMG 592, these innovations offer promising solutions to fine-tune IL-2 therapy. 🧪💡 As we delve deeper into the realm of immunotherapy, understanding these nuances becomes crucial. IL-2 is playing a pivotal role in this fascinating journey. 🚀 Read more https://lnkd.in/eqQdg2U5 #Immunotherapy #Tregs #IL2 #AutoimmuneDisease #TranslationalResearch

𝐃𝐞𝐧𝐝𝐫𝐢𝐭𝐢𝐜 𝐂𝐞𝐥𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐃𝐞𝐧𝐝𝐫𝐢𝐭𝐢𝐜 𝐂𝐞𝐥𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/db9Tu4g9 #Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. The report presents comprehensive understanding of the Dendritic #Cell Cancer Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Dendritic Cell Cancer Vaccine industry. Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Dendritic Cell #Cancer Vaccine market. *𝗕𝘆 𝗧𝘆𝗽𝗲: CreaVax, Sipuleucel-T (Provenge) *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Pediatrics, Adults *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝘀: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Activarti, Argos, SOTIO Biotech (Acquired by PPF Group), Bellicum Pharmaceuticals, Inc., JW CreaGene, DANDRITE, DCPrime B.V., Elios Therapeutics, LLC, ImmunoCellular Therapeutics Ltd, Kiromic Biopharma, Inc., Medigene AG, Merck Group, Northwest Biotherapeutics, Immutep Limited, Dendreon, Oncobiomed Advanced Cells Technologies #DendriticCells #CancerVaccine #Immunotherapy #CancerResearch #MedicalInnovation #Oncology #Biotechnology #Healthcare #ClinicalTrials #CancerTreatment #PrecisionMedicine #TumorImmunology #MedicalTechnology #BiotechIndustry #ResearchAndDevelopment #CancerAwareness #HealthTech #ScienceAndMedicine #CancerPrevention #Immunology

𝐃𝐞𝐧𝐝𝐫𝐢𝐭𝐢𝐜 𝐂𝐞𝐥𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐃𝐞𝐧𝐝𝐫𝐢𝐭𝐢𝐜 𝐂𝐞𝐥𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/db9Tu4g9 #Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. The report presents comprehensive understanding of the Dendritic #Cell Cancer Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Dendritic Cell Cancer Vaccine industry. Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Dendritic Cell #Cancer Vaccine market. *𝗕𝘆 𝗧𝘆𝗽𝗲: CreaVax, Sipuleucel-T (Provenge) *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Pediatrics, Adults *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝘀: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Activarti, Argos, SOTIO Biotech (Acquired by PPF Group), Bellicum Pharmaceuticals, Inc., JW CreaGene, DANDRITE, DCPrime B.V., Elios Therapeutics, LLC, ImmunoCellular Therapeutics Ltd, Kiromic Biopharma, Inc., Medigene AG, Merck Group, Northwest Biotherapeutics, Immutep Limited, Dendreon, Oncobiomed Advanced Cells Technologies #DendriticCells #CancerVaccine #Immunotherapy #CancerResearch #MedicalInnovation #Oncology #Biotechnology #Healthcare #ClinicalTrials #CancerTreatment #PrecisionMedicine #TumorImmunology #MedicalTechnology #BiotechIndustry #ResearchAndDevelopment #CancerAwareness #HealthTech #ScienceAndMedicine #CancerPrevention #Immunology

In Episode 5 of our Pipeline Analysis series, we analysed the innovative strides made by GSK. Here are some key takeaways: -The company reported an impressive revenue of £7.4 billion in Q1 2024, supporting a robust pipeline of 91 development programs, including 62 New Molecular Entities. -GSK's pipeline is strategically distributed across various phases, with 24% in Phase 1, 46% in Phase 2, and 25% in Phase 3. This diverse portfolio spans therapeutic areas such as oncology, immunology, respiratory diseases, vaccines, and infectious diseases. -Committed to innovation, GSK allocates approximately 18% of its revenue towards pipeline development, highlighting its dedication to advancing healthcare solutions and improving patient outcomes. Stay tuned for more profound insights and updates from RAS LifeScience Solutions! #GSK #PipelineAnalysis #Innovation #Healthcare #Biopharmaceuticals #FutureOfMedicine

BenevolentAI announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification Read More: https://lnkd.in/dGm6a2s8 “Following our recent success in the area of heart failure, I’m delighted that AstraZeneca has selected a novel target for SLE to enter its portfolio. The continued, fruitful efforts of our two companies working in collaboration will help bring potential new therapeutic options to lupus patients, whose quality of life is often severely limited by the disease.” Said Dr Anne Phelan, Chief Scientific Officer of BenevolentAI “Our aim is to lead in lupus by continuing to discover and develop novel treatments that push the efficacy ceiling for patients, allowing more people to achieve remission. By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” Said Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca. #mededgemea #benevolentai #AstraZeneca #pharmacollaboration #DrugDiscovery #aiinhealthcare #medicalresearch #lupus #autoimmunedisease #innovativemedicine #healthtech

Amgen has reported positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) HCP (inebilizumab-cdon) for the treatment of Immunoglobulin G4-related disease (IgG4-RD). Uplizna, an antibody therapy already with FDA approval for neuromyelitis optica spectrum disorder, is based on technology licensed from Duke University, developed by the late Duke University School of Medicine Dr. Thomas Tedder and colleagues. MITIGATE was conducted at 80 sites in 22 countries. It is the first placebo-controlled trial providing class 1 evidence for treating IgG4-RD, a chronic, systemic, immune-mediated, fibroinflammatory disease that can affect almost any organ in the body, often involving multiple organs at a time, and can result in irreversible organ damage. The novel, steroid-sparing study design paves the way for a reduced toxicity treatment approach. Based on the MITIGATE primary analysis results, Amgen is planning to file for approval in the U.S. followed by other key markets. https://lnkd.in/enXafGUh #innovation #techtransfer #licensing #immune #IgG4RD #NMOSD #autoimmune #therapeutic

Episode 5 of Pipeline Analysis series is out. Have a look!!